Clinical Trial Update: Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating an anti-PD-1 antibody in combination with high-dose interleukin-2 for metastatic melanoma has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Anti-PD-1 antibody
• Interleukin-2 (high-dose) (Interleukin-2)

Snippet

Sponsor: Ralph Hauke | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2024-10-02